1
|
Guski LS, Jürgens G, Pedder H, Levinsen NKG, Andersen SE, Welton NJ, Graudal N. Monotreatment With Conventional Antirheumatic Drugs or Glucocorticoids in Rheumatoid Arthritis: A Network Meta-Analysis. JAMA Netw Open 2023; 6:e2335950. [PMID: 37801318 PMCID: PMC10559183 DOI: 10.1001/jamanetworkopen.2023.35950] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/23/2023] [Accepted: 08/22/2023] [Indexed: 10/07/2023] Open
Abstract
Importance This is the first network meta-analysis to assess outcomes associated with multiple conventional synthetic disease-modifying antirheumatic drugs and glucocorticoid. Objective To analyze clinical outcomes after treatment with conventional synthetic disease-modifying antirheumatic drugs and glucocorticoid among patients with rheumatoid arthritis. Data Sources With no time restraint, English language articles were searched in MEDLINE, Embase, Cochrane Central, ClinicalTrials.gov, and reference lists of relevant meta-analyses until September 15, 2022. Study Selection Four reviewers in pairs of 2 independently included controlled studies randomizing patients with rheumatoid arthritis to mono-conventional synthetic disease-modifying antirheumatic drugs, glucocorticoid, placebo, or nonactive treatment that recorded at least 1 outcome of tender joint count, swollen joint count, erythrocyte sedimentation rate, and C-reactive protein level. Of 1098 assessed articles, 130 articles (132 interventions) were included. Data Extraction and Synthesis The review followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses reporting guideline, and data quality was assessed by the Cochrane risk of bias tool RoB 2. Data were extracted by a single author and checked independently by 2 authors. Data were analyzed using a random effect model, and data analysis was conducted from June 2021 to February 2023. Main Outcomes and Measures A protocol with hypothesis and study plan was registered before data recording. The most complete of recorded outcomes (tender joint count) was used as primary outcome, with imputations based on other outcomes to obtain a full analysis of all studies. Absolute change adjusted for baseline disease activity was assessed. Results A total of 29 interventions in 275 treatment groups among 132 randomized clinical trials (mean [range], 71.0% [27.0% to 100%] females in studies; mean [range] of ages in studies, 53 [36 to 70] years) were identified, which included 13 260 patients with rheumatoid arthritis. The mean (range) duration of RA was 79 (2 to 243) months, and the mean (range) disease activity score was 6.3 (4.0 to 8.8). Compared with placebo, oral methotrexate was associated with a reduced tender joint count by 5.18 joints (95% credible interval [CrI], 4.07 to 6.28 joints). Compared with methotrexate, glucocorticoid (-2.54 joints; 95% CrI, -5.16 to 0.08 joints) and remaining drugs except cyclophosphamide (6.08 joints; 95% CrI, 0.44 to 11.66 joints) were associated with similar or lower tender joint counts. Conclusions and Relevance This study's results support the present role of methotrexate as the primary reference conventional synthetic disease-modifying antirheumatic drug.
Collapse
Affiliation(s)
- Louise S. Guski
- Clinical Pharmacology Unit, Zealand University Hospital, Roskilde, Denmark
| | - Gesche Jürgens
- Clinical Pharmacology Unit, Zealand University Hospital, Roskilde, Denmark
| | - Hugo Pedder
- Department of Population Health Science, Bristol Medical School, University of Bristol, Bristol, United Kingdom
| | | | - Stig E. Andersen
- Clinical Pharmacology Unit, Zealand University Hospital, Roskilde, Denmark
| | - Nicky J. Welton
- Department of Population Health Science, Bristol Medical School, University of Bristol, Bristol, United Kingdom
| | - Niels Graudal
- Center for Rheumatology and Spine Diseases, The Lupus and Vasculitis Clinic, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
| |
Collapse
|
2
|
Ratiometric fluorescence and colorimetric dual-mode sensing platform based on carbon dots for detecting copper(II) ions and D-penicillamine. Anal Bioanal Chem 2022; 414:1651-1662. [DOI: 10.1007/s00216-021-03789-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2021] [Revised: 10/27/2021] [Accepted: 11/11/2021] [Indexed: 11/01/2022]
|
3
|
Cao Y, Khan A, Balakheyli H, Lup ANK, Ramezani Taghartapeh M, Mirzaei H, Reza Khandoozi S, Soltani A, Aghaei M, Heidari F, Sarkar SM, Albadarin AB. Penicillamine functionalized B12N12 and B12CaN12 nanocages act as potential inhibitors of proinflammatory cytokines: A combined DFT analysis, ADMET and molecular docking study. ARAB J CHEM 2021. [DOI: 10.1016/j.arabjc.2021.103200] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
|
4
|
Nakamoto K, Tanaka Y, Sasaki Y, Goto H. Bucillamine-induced interstitial pneumonitis. J Gen Fam Med 2018; 19:111-112. [PMID: 29744266 PMCID: PMC5931345 DOI: 10.1002/jgf2.169] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2017] [Accepted: 03/02/2018] [Indexed: 11/07/2022] Open
Abstract
We diagnosed as bucillamine‐induced interstitial pneumonitis and were able to observe changes in pulmonary lesions and therapeutic effects by using HRCT.
![]()
Collapse
Affiliation(s)
- Keitaro Nakamoto
- Department of Respiratory MedicineJapan Anti‐Tuberculosis AssociationFukujuji HospitalTokyoJapan
| | - Yoshiaki Tanaka
- Department of Respiratory MedicineJapan Anti‐Tuberculosis AssociationFukujuji HospitalTokyoJapan
| | - Yuka Sasaki
- Department of Respiratory MedicineJapan Anti‐Tuberculosis AssociationFukujuji HospitalTokyoJapan
| | - Hajime Goto
- Department of Respiratory MedicineJapan Anti‐Tuberculosis AssociationFukujuji HospitalTokyoJapan
| |
Collapse
|
5
|
Jafari M, Tashkhourian J, Absalan G. Electrochemical sensing of D-penicillamine on modified glassy carbon electrode by using a nanocomposite of gold nanoparticles and reduced graphene oxide. JOURNAL OF THE IRANIAN CHEMICAL SOCIETY 2017. [DOI: 10.1007/s13738-017-1076-2] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
6
|
Bykerk VP. Nonimmunosuppressive disease-modifying antirheumatic drugs. Rheumatology (Oxford) 2015. [DOI: 10.1016/b978-0-323-09138-1.00055-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
7
|
Walekar LS, Kondekar UR, Gore AH, Pawar SP, Sudarsan V, Anbhule PV, Patil SR, Kolekar GB. Ultrasensitive, highly selective and naked eye colorimetric recognition ofd-penicillamine in aqueous media by CTAB capped AgNPs: applications to pharmaceutical and biomedical analysis. RSC Adv 2014. [DOI: 10.1039/c4ra05741d] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
8
|
Nakajima M, Ueda N, Ohara H, Abe M, Kinoshita M. A comparative study of the effects of bucillamine and salazosulfapyridine in the treatment of rheumatoid arthritis. Mod Rheumatol 2014. [DOI: 10.3109/s10165-009-0169-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
9
|
Sekiguchi N, Kameda H, Amano K, Takeuchi T. Efficacy and safety of bucillamine, ad-penicillamine analogue, in patients with active rheumatoid arthritis. Mod Rheumatol 2014. [DOI: 10.3109/s10165-005-0466-y] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
10
|
Ensafi AA, Karimi-Maleh H, Mallakpour S. N-(3,4-Dihydroxyphenethyl)-3,5-dinitrobenzamide-Modified Multiwall Carbon Nanotubes Paste Electrode as a Novel Sensor for Simultaneous Determination of Penicillamine, Uric acid, and Tryptophan. ELECTROANAL 2011. [DOI: 10.1002/elan.201000741] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
11
|
Ultraviolet derivatization of low-molecular-mass thiols for high performance liquid chromatography and capillary electrophoresis analysis. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879:1290-307. [DOI: 10.1016/j.jchromb.2010.10.035] [Citation(s) in RCA: 92] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2010] [Revised: 10/20/2010] [Accepted: 10/28/2010] [Indexed: 11/30/2022]
|
12
|
Toyo’oka T. Recent advances in separation and detection methods for thiol compounds in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877:3318-30. [DOI: 10.1016/j.jchromb.2009.03.034] [Citation(s) in RCA: 142] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2009] [Revised: 03/19/2009] [Accepted: 03/23/2009] [Indexed: 11/28/2022]
|
13
|
Kuśmierek K, Chwatko G, Głowacki R, Bald E. Determination of endogenous thiols and thiol drugs in urine by HPLC with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877:3300-8. [DOI: 10.1016/j.jchromb.2009.03.038] [Citation(s) in RCA: 95] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2009] [Revised: 03/20/2009] [Accepted: 03/25/2009] [Indexed: 10/20/2022]
|
14
|
Nakajima M, Ueda N, Ohara H, Abe M, Kinoshita M. A comparative study of the effects of bucillamine and salazosulfapyridine in the treatment of rheumatoid arthritis. Mod Rheumatol 2009; 19:384-9. [PMID: 19363607 DOI: 10.1007/s10165-009-0169-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2008] [Accepted: 03/16/2009] [Indexed: 11/29/2022]
Abstract
Bucillamine (Buc), developed in Japan, is a disease-modifying antirheumatic drug (DMARD) which has been used to treat numerous patients with rheumatoid arthritis (RA) in Japan and Korea with favorable results. However, it has not been used globally. In the present study, we compared the timing of onset of efficacy and the usefulness of this drug with that of the globally accepted agent salazosulfapyridine (SASP). There were 26 patients in the Buc group and 23 in the SASP group. We compared changes in the number of swollen joints, number of painful joints, duration of morning stiffness, grip strength, levels of inflammatory marker [erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)], rheumatoid factor (RF), physician's rating by visual analogue scale (VAS), patient's rating of pain, patient's overall rating (VAS), and improvement according to European League against Rheumatism (EULAR) criteria (DAS28-CRP, DAS28-ESR) in these two groups of patients. Both Buc and SASP were shown to be efficacious within 3 months after the start of treatment. Both drugs were found to be suitable as first-line treatment of early RA. Signs of efficacy tended to occur earlier with Buc than with SASP, and Buc also tended to have higher efficacy than SASP.
Collapse
Affiliation(s)
- Mikio Nakajima
- Department of Orthopedic Surgery, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka 569-8686, Japan.
| | | | | | | | | |
Collapse
|
15
|
Li N, Kwak J. A Penicillamine Biosensor Based on Tyrosinase Immobilized on Nano-Au/ PAMAM Dendrimer Modified Gold Electrode. ELECTROANAL 2007. [DOI: 10.1002/elan.200703968] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
16
|
Raoof JB, Ojani R, Chekin F. Electrochemical Analysis ofD-Penicillamine Using a Carbon Paste Electrode Modified with Ferrocene Carboxylic Acid. ELECTROANAL 2007. [DOI: 10.1002/elan.200703947] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
17
|
Kuśmierek K, Bald E. Simultaneous determination of tiopronin and d-penicillamine in human urine by liquid chromatography with ultraviolet detection. Anal Chim Acta 2007; 590:132-7. [PMID: 17416233 DOI: 10.1016/j.aca.2007.03.025] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2007] [Revised: 03/09/2007] [Accepted: 03/13/2007] [Indexed: 10/23/2022]
Abstract
d-Penicillamine and tiopronin are drugs widely used for the treatment of many diseases. Because of the relatively high frequency of side effects to these compounds, some of which are dose-related, drug monitoring in urine samples during treatment is advisable. In this paper, we describe a simple method for the determination of tiopronin and d-penicillamine in human urine. The method was based on derivatization with 2-chloro-1-methylquinolinium tetrafluoroborate followed by ion-pairing reversed-phase liquid chromatography separation and ultraviolet-absorbance detection. 2-S-quinolinium derivatives of thiols were detected at 355 nm. The derivatization was optimized in terms of pH and time of the reaction. Baseline separation was achieved on an analytical Zorbax SB C-18 (5 microm, 150 mm x 4.6 mm) column with a mobile phase consisting of pH 2.0 0.09 mol L(-1) trichloroacetic acid buffer (component A) and acetonitrile (component B) pumped at 1.0 mL min(-1). Gradient elution was used: 0-4 min, 12% B; 4-8 min, 12-40% B; 8-12 min, 40-12% B. The d-penicillamine and tiopronin standards added to the urine show that the response of the detector is linear within the range studied, from 1 to 200 micromol L(-1) urine. The imprecision ranges for tiopronin and d-penicillamine were within 1.61-8.24% and 2.92-10.60%, respectively. The analytical accuracy for determined compounds was from 97.24 to 109.39%. The lower limits of detection and quantitation were 0.5 micromol L(-1) and 1.0 micromol L(-1) urine, respectively. This method can be used for routine clinical monitoring of the title thiol-drugs. Cysteine can be measured concurrently, if needed.
Collapse
Affiliation(s)
- Krzysztof Kuśmierek
- Department of Environmental Chemistry, University of Lodz, 163 Pomorska Str., 90-236 Lodz, Poland
| | | |
Collapse
|
18
|
Sekiguchi N, Kameda H, Amano K, Takeuchi T. Efficacy and safety of bucillamine, a D-penicillamine analogue, in patients with active rheumatoid arthritis. Mod Rheumatol 2006; 16:85-91. [PMID: 16633927 DOI: 10.1007/s10165-005-0466-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2005] [Accepted: 02/21/2006] [Indexed: 10/24/2022]
Abstract
Japanese rheumatologists consider bucillamine (Buc) to be a useful disease-modifying antirheumatic drug (DMARD) and often give Buc to patients with rheumatoid arthritis (RA) prior to administering methotrexate (MTX). However, no large studies on the efficacy and safety of Buc in RA patients have been published in English to date. We therefore investigated the clinical course of RA patients treated with Buc and compared the results with those for patients treated with MTX to evaluate and confirm the place of Buc in therapeutic strategies for RA in Japan. Our results suggested that Buc should be given to patients with moderately active RA either before or after the administration of MTX because its efficacy can be judged within 3 months and because serious adverse events are rare. Issues like the ability of Buc to prevent joint destruction and its efficacy and safety when combined with agents like etanercept require future study.
Collapse
Affiliation(s)
- Naoya Sekiguchi
- Division of Rheumatology/Clinical Immunology, Department of Internal Medicine, Saitama Medical Center, 1981 Tsujido-machi, Kamoda, Kawagoe, 350-8550, Japan.
| | | | | | | |
Collapse
|
19
|
Distler JHW, Hagen C, Hirth A, Müller-Ladner U, Lorenz HM, del Rosso A, Michel BA, Gay RE, Nanagara R, Nishioka K, Matucci-Cerinic M, Kalden JR, Gay S, Distler O. Bucillamine Induces the Synthesis of Vascular Endothelial Growth Factor Dose-Dependently in Systemic Sclerosis Fibroblasts via Nuclear Factor-κB and Simian Virus 40 Promoter Factor 1 Pathways. Mol Pharmacol 2004; 65:389-99. [PMID: 14742681 DOI: 10.1124/mol.65.2.389] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
The pathogenesis of systemic sclerosis (SSc) is characterized by activation of the immune system, impaired angiogenesis, and activated dermal fibroblasts. The effects of the immunosuppressive agent bucillamine (SA 96) on fibroblasts and angiogenic factors have not been examined. SA 96, and particularly its metabolite SA 981, increased the levels of vascular endothelial growth factor (VEGF) mRNA and protein dose-dependently in dermal fibroblasts from patients with SSc and healthy control subjects without influencing cell viability. SSc fibroblast cultures showed consistently a higher inducibility of VEGF than cultures from healthy control subjects. Preincubation with the SP-1 inhibitor mithramycin as well as blockade of nuclear factor (NF)-kappaB signaling with pyrrolidine dithiocarbamate treatment and IkappaB transfection reduced significantly the transcription of VEGF, indicating that both transcription factors contribute to the activation of VEGF by SA 981. Specific binding of NF-kappaB protein to its binding site after treatment with SA 981 was confirmed by electrophoretic mobility shift assay. In contrast, SA 981 did not influence the stability of VEGF mRNA as analyzed with actinomycin D assays. The study provides evidence for a role of NF-kappaB in the transcriptional regulation of the VEGF gene. SA 96 might have positive aspects on the impaired angiogenesis in patients with SSc.
Collapse
Affiliation(s)
- Jörg H W Distler
- Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Hikichi T, Mori F, Nakamura M, Shishido N, Sasaki M, Horikawa Y, Yoshida A. Inhibitory effects of bucillamine on increased blood-retinal barrier permeability in streptozotocin-induced diabetic rats. Curr Eye Res 2002; 25:1-7. [PMID: 12518237 DOI: 10.1076/ceyr.25.1.1.9962] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
PURPOSE To investigate the effect of bucillamine for prevention of increasing blood-retinal barrier (BRB) permeability in streptozotocin (STZ)-induced diabetic rats. METHODS The groups included control and STZ-induced diabetic rats treated with or without bucillamine. Six months after intervention, the concentrations of reduced and oxidative glutathione (GSH and GSSG) in the retina were measured biochemically. In addition, vitreous fluorescein, which leaks from the vessels after intravenous injection of fluorescein sodium, was measured to evaluate BRB permeability. To evaluate the scavenging ability against the reactive oxygen species (ROS) in vitro, the second-order rate constant for the reaction of bucillamine with ROS was estimated from the kinetics based on the rate constant for the reaction of ROS. RESULTS The BRB permeability was significantly higher (p = 0.01) in diabetic rats not treated with bucillamine, and bucillamine inhibited the BRB permeability. The GSH concentration and the GSH/GSSG ratio in the retinas decreased in diabetic rats not treated with bucillamine; bucillamine inhibited the decrease of the GSH concentrations. The ROS scavenging activity of bucillamine was similar with that of GSH. CONCLUSIONS In diabetic retinas, oxidative stress might increase, which may be one of the causes of BRB breakdown. The antioxidant effects of bucillamine might take part in inhibition of increased permeability of the BRB in diabetes.
Collapse
Affiliation(s)
- Taiichi Hikichi
- Department of Ophthalmology, Asahikawa Medical College, Asahikawa, Japan.
| | | | | | | | | | | | | |
Collapse
|
21
|
Nagahama K, Matsushita H, Hara M, Ubara Y, Hara S, Yamada A. Bucillamine induces membranous glomerulonephritis. Am J Kidney Dis 2002; 39:706-12. [PMID: 11920335 DOI: 10.1053/ajkd.2002.31987] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
A variety of renal histopathologic lesions, such as amyloidosis, mesangial proliferative glomerulonephritis, and membranous glomerulonephritis (MGN), are associated with rheumatoid arthritis (RA). Bucillamine (BCL), a disease-modifying antirheumatic drug, has a chemical structure and side-effect profile similar to that of d-penicillamine, which can induce MGN in RA. There are a few reports of MGN occurring in association with BCL treatment. However, lacking detailed analyses of immunoglobulin deposition in glomerular lesions, these studies did not elucidate the pathogenesis of BCL-induced MGN. We evaluated seven biopsy specimens from six patients with RA who had undergone BCL treatment with a mean BCL dose of 72.5 g before the appearance of proteinuria. Light microscopic evaluation showed mild to moderate mesangial proliferation. Two biopsy specimens showed spikes along glomerular capillary walls. Granular deposition of immunoglobulin G (IgG) along glomerular capillary walls was seen in all cases, and five specimens showed deposition of IgG2 and/or IgG3 components, in addition to IgG4. Furthermore, subepithelial dense deposits were distributed segmentally in four biopsy specimens on electron microscopy. IgG4, reported to be the predominant IgG subclass deposited, is distributed diffusely in idiopathic MGN. Thus, there were obvious differences between BCL-induced and idiopathic MGN in regard to both IgG subclasses deposited and deposition pattern within the glomerulus. Because IgG3 has the strongest affinity for C1q, these findings suggest that BCL-induced MGN activates the classical pathway more efficiently than idiopathic MGN and that the pathogenesis is different between these two diseases.
Collapse
Affiliation(s)
- Kiyotaka Nagahama
- Department of Pathology, Yokohama City University School of Medicine, Kanagawa, Japan.
| | | | | | | | | | | |
Collapse
|
22
|
Gigante A, Chillemi C, Quaglino D, Miselli M, Pasquali-Ronchetti I. DL-penicillamine induced alteration of elastic fibers of periosteum-perichondrium and associated growth inhibition: an experimental study. J Orthop Res 2001; 19:398-404. [PMID: 11398852 DOI: 10.1016/s0736-0266(00)90033-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Perichondrium-periosteum, being of collagen and elastic fiber, is regarded as a bone growth regulating factor. The aim of the present study was to investigate the role of collagen and elastic fibers on bone growth, by interfering with the fiber assembly in growing chicks upon administration of DL-penicillamine (DL-PNA). Our findings demonstrated that DL-PNA determined relevant modifications in the perichondrium-periosteum, as shown by histochemical, histomorphometrical,biochemical and ultrastructural analysis. This chemical has been shown to inhibit the formation of desmosine cross-links in elastin and to induce an increase of elastin associated microfibrils. On the contrary, the collagen network and the biochemical collagen markers were not affected. These changes resulted in a dramatically reduced growth of long bones in comparison with control. Perichondrial-periosteal regulation of bone growth may be mediated by mechanical and biological factors. This study demonstrates a microstructural change in the perichondrium-periosteum with decreased elastin and increased elastic microfibrils content in penicillamine treated chicks. The mechanism linking changes in the perichondrium-periosteum with altered growth still needs to be elucidated.
Collapse
Affiliation(s)
- A Gigante
- Clinica Ortopedica, Ospedale Umberto I, Universitá degli Studi di Ancona, Italy.
| | | | | | | | | |
Collapse
|